6895
document
Olanzapine versus haloperidol in children with autistic disorder : an open pilot study . OBJECTIVES Conventional neuroleptics ameliorate symptoms in children with autistic disorder ; however , they are known to cause dyskinesias . Atypical neuroleptics , including olanzapine , may have less risk for dyskinesia , but their efficacy in autistic disorder is not established . This study was designed to investigate the safety and effectiveness of open-label olanzapine as a treatment for children with autistic disorder by using haloperidol as a standard comparator treatment . METHOD In a parallel groups design , 12 children with DSM-IV autistic disorder ( mean age 7.8+/-2.1 years ) were randomized to 6 weeks of open treatment with olanzapine or haloperidol . Mean final dosages were 7.9+/-2.5 mg/day for olanzapine and 1.4+/-0.7 mg/day for haloperidol . Outcome measures included the Clinical Global Impressions ( CGI ) and the Children 's Psychiatric Rating Scale ( CPRS ) . RESULTS Both groups had symptom reduction . Five of six in the olanzapine group and three of six in the haloperidol group were rated as responders according to the CGI Improvement item . Subjects showed improvement on the CPRS Autism Factor ( F1,9 = 24.4 , p = .0008 ) . Side effects included drowsiness and weight gain . CONCLUSIONS The findings suggest that olanzapine is a promising treatment for children with autistic disorder . Further placebo-controlled and long-term studies of olanzapine in autistic disorder are required .
6896
Intervention_Pharmacological
Olanzapine
6897
Intervention_Pharmacological
haloperidol
6898
Intervention_Pharmacological
neuroleptics
6899
Intervention_Pharmacological
Atypical neuroleptics
6900
Intervention_Pharmacological
olanzapine
6901
Intervention_Pharmacological
haloperidol
6902
Intervention_Pharmacological
open treatment with olanzapine
6903
Intervention_Pharmacological
haloperidol
6904
Intervention_Pharmacological
olanzapine
6905
Intervention_Pharmacological
haloperidol
6906
Intervention_Pharmacological
olanzapine
6907
Intervention_Pharmacological
haloperidol
6908
Intervention_Pharmacological
olanzapine
6909
Intervention_Pharmacological
olanzapine
6910
Outcome_Mental
Clinical Global Impressions ( CGI )
6911
Outcome_Mental
the Children 's Psychiatric Rating Scale ( CPRS )
6912
Outcome_Mental
symptom reduction
6913
Outcome_Mental
CGI
6914
Outcome_Mental
CPRS Autism Factor
6915
Outcome_Adverse-effects
drowsiness and weight gain
6916
Participant_Age
children
6917
Participant_Condition
autistic disorder
6918
Participant_Age
children
6919
Participant_Condition
autistic disorder ;
6920
Participant_Age
children
6921
Participant_Condition
autistic disorder
6922
Participant_Condition
DSM-IV autistic disorder
6923
Participant_Age
mean age 7.8+/-2.1 years
6924
Participant_Age
children
6925
Participant_Condition
autistic disorder